Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia (pages 2583–2591)
Apostolia M. Tsimberidou, Michael J. Keating, Francis J. Giles, William G. Wierda, Alessandra Ferrajoli, Susan Lerner, Miloslav Beran, Michael Andreeff, Hagop M. Kantarjian and Susan O'Brien
Version of Record online: 6 MAY 2004 | DOI: 10.1002/cncr.20264
In a cohort of 88 patients with B-cell chronic lymphocytic leukemia (CLL) who were treated with a regimen containing fludarabine and mitoxantrone (FN), response rates were 83% in previously untreated patients, 87% in patients who were treated previously with alkylating agents, 50% in patients who had disease that was not refractory to fludarabine at the start of therapy, and 25% in patients who had disease that was refractory to fludarabine. With a median follow-up of 8 years for surviving patients, the median progression-free survival was 24 months for all patients and 34 months for previously untreated patients, the median overall survival was 40 months, and the median survival of previously untreated patients was 88 months. The FN regimen was not superior to fludarabine alone in patients with B-cell CLL.